Vol. 6 Issue 3 Part B

Background: The aim of the study is to evaluate thrombocytopenia in alcohol withdrawal symptoms (AWS) as a predictive marker for non-severe alcohol withdrawal symptoms (nAWS) to severe alcohol withdrawal symptoms (sAWS) and its relationship with liver enzymes.

Methodology: A 3 months (forty-three patients) prospective study during June 2023 to August 2023 was carried out in patient admitted at B. J. Medical College with complains of symptoms related with alcohol withdrawal. Detailed history and evaluation regarding alcohol dependence along with laboratory parameters like CBC, LFT, RFT at regular intervals was carried out. On achieving the diagnostic criteria of alcohol withdrawal symptoms patients was treated and discharge.

Result: During the treatment period out of 43 patients, 9 (21%) were having complains of sAWS out of which 7 had reduced platelet counts and remaining 34 (79%) were having complains of nAWS. Liver enzyme (Alanine transaminase (ALT)) was higher in 28% (12/43) of patients ranging from (42-178 IU/L) which was a significant risk factor (p<0.05) for severe alcohol withdrawal symptoms and there was no association of potassium level with sAWS.

Conclusion: Thrombocytopenia is more frequent in patients with sAWS and it shows reverse thrombocytosis during the course of treatment.